journal article·2026-04Open access

Hypoxia-responsive self-assembled nanoparticles for reprogramming tumor-associated macrophages into an anti-tumor M1 phenotype in breast cancer

Xiaoyan Fu, Huayong Zhang, Weimin Liu, Tingting Wu, Yizi Zheng

Abstract

The tumor microenvironment is characterized by hypoxia, resulting mainly from aberrant vascularization and insufficient blood perfusion. Under such hypoxic conditions, tumor-associated macrophages (TAMs) preferentially polarize toward an immunosuppressive M2-like phenotype, which promotes immune evasion and accelerates tumor progression. Reprogramming these M2-like TAMs into an anti-tumor M1 phenotype represents a promising therapeutic strategy, yet it remains a substantial challenge. In this study, we developed nanoparticles functionalized with mannose and an MMP-2-responsive PLGVRGD peptide. These nanoparticles undergo self-assembly in the presence of matrix metalloproteinase-2 (MMP-2), which is highly expressed in hypoxic tumor regions. The high-density mannose residues on the nanoparticle surface facilitate efficient binding to M2-like TAMs and promote their repolarization to the M1 phenotype. Moreover, the resulting system exhibits enhanced tumor tissue penetration and effectively reverses the immunosuppressive tumor microenvironment, supporting its potential as a targeted nanotherapeutic strategy for breast cancer.
Source: openalex_inverted_index · Quality: baseline

Research context

OpenAlex topics: Immune cells in cancer · Nanoplatforms for cancer theranostics · Nanoparticle-Based Drug Delivery

SciVX discovery tags are terminology-based. OpenAlex topics are source-provided classifications.

References (64)

Show source-provided references
1. Role of hypoxia in cancer therapy by regulating the tumor microenvironment10.1186/s12943-019-1089-9 ↗
2. Recent advancements of nanotechnology-based strategies for overcoming tumor microenvironment hypoxia10.31083/j.fbl2705145 ↗
3. Normalization of the vasculature for treatment of cancer and other diseases10.1152/physrev.00038.2010 ↗
4. Hypoxia accelerates the progression of angiosarcoma through the regulation of angiosarcoma cells and tumor microenvironment10.1016/j.jdermsci.2019.01.005 ↗
5. Hypoxia-induced myeloid derived growth factor promotes hepatocellular carcinoma progression through remodeling tumor microenvironment10.7150/thno.49327 ↗
6. Responsive role of nanomedicine in the tumor microenvironment and cancer drug resistance10.2174/0929867329666220922111336 ↗
7. Hypoxia-inducible factor-dependent ADAM12 expression mediates breast cancer invasion and metastasis10.1073/pnas.2020490118 ↗
8. Hypoxia-inducible factors: master regulators of hypoxic tumor immune escape10.1186/s13045-022-01292-6 ↗
9. Aspects of the tumor microenvironment involved in immune resistance and drug resistance10.3389/fimmu.2021.656364 ↗
10. Macrophage polarization states in the tumor microenvironment10.3390/ijms22136995 ↗
11. The hypoxia-driven crosstalk between tumor and tumor-associated macrophages: mechanisms and clinical treatment strategies10.1186/s12943-022-01645-2 ↗
12. Hypoxic tumor-derived exosomal miR-301a mediates M2 macrophage polarization via PTEN/PI3Kγ to promote pancreatic cancer metastasis10.1158/0008-5472.CAN-17-3841 ↗
13. MicroRNA-301a inhibition enhances the immunomodulatory functions of adipose-derived mesenchymal stem cells by induction of macrophage M2 polarization10.1177/2058738420966092 ↗
14. Correction: hypoxic tumor-derived exosomal miR-301a mediates M2 macrophage polarization via PTEN/PI3Kγ to promote pancreatic cancer metastasis10.1158/0008-5472.CAN-19-3872 ↗
15. Hypoxia-driven tumor stromal remodeling and immunosuppressive microenvironment in scirrhous HCC10.1097/HEP.0000000000000599 ↗
16. Ginseng-derived nanoparticles alter macrophage polarization to inhibit melanoma growth10.1186/s40425-019-0817-4 ↗
17. Targeting tumor-associated macrophages in the tumor microenvironment10.3892/ol.2020.12097 ↗
18. Tumor microenvironment-responsive delivery nanosystems reverse immunosuppression for enhanced CO gas/immunotherapy
19. Oxygen-carrying nanoplatform to reprogram tumor immunosuppressive microenvironment and enhance photothermal-immunotherapy
20. Bioengineered nanogels for cancer immunotherapy10.1039/D2CS00247G ↗
21. Therapeutic copolymer from salicylic acid and l-Phenylalanine as a nanosized drug carrier for orthotopic breast cancer with lung metastasis10.1021/acsami.3c08608 ↗
22. Stimuli-responsive nanocarriers for drug delivery10.1038/nmat3776 ↗
23. Nano based drug delivery systems: recent developments and future prospects10.1186/s12951-018-0392-8 ↗
24. Deformable nanocarriers for enhanced drug delivery and cancer therapy
25. Tumor microenvironment as a therapeutic target in cancer10.1016/j.pharmthera.2020.107753 ↗
26. Tumor microenvironment10.3390/medicina56010015 ↗
27. Macrophages and metabolism in the tumor microenvironment10.1016/j.cmet.2019.06.001 ↗
28. Pathological environment directed in situ peptidic supramolecular assemblies for nanomedicines10.1088/1748-605X/abc2e9 ↗
29. Near-infrared laser-driven in situ self-assembly as a general strategy for deep tumor therapy10.1021/acs.nanolett.8b03174 ↗
30. Enzyme-mediated in situ self-assembly promotes in vivo bioorthogonal reaction for pretargeted multimodality imaging10.1002/anie.202103307 ↗
31. In situ orderly self-assembly strategy affording NIR-II-J-aggregates for in vivo imaging and surgical navigation10.1038/s41467-023-37586-7 ↗
32. Hypoxia-triggered in situ self-assembly of a charge switchable azo polymer with AIEgens for tumor imaging10.1021/acsmacrolett.1c00183 ↗
33. Nanomedicine in cancer therapy10.1038/s41392-023-01536-y ↗
34. Current perspectives and trend of nanomedicine in cancer: a review and bibliometric analysis10.1016/j.jconrel.2022.10.023 ↗
35. In situ self-assembly for cancer therapy and imaging10.1038/s41578-023-00589-3 ↗
36. Self-adaptive nanoassembly enabling turn-on hypoxia illumination and periphery/center closed-loop tumor eradication
37. Immunostimulation of tumor microenvironment by targeting tumor-associated macrophages with hypoxia-responsive nanocomplex for enhanced anti-tumor therapy10.1016/j.jconrel.2022.01.021 ↗
38. New opportunities for immunomodulation of the tumour microenvironment using chemical tools10.1039/D2CS00486K ↗
39. Rediscovery of mononuclear phagocyte system blockade for nanoparticle drug delivery10.1038/s41467-024-48838-5 ↗
40. Fluorinated PLGA-PEG-Mannose nanoparticles for tumor-associated macrophage detection by optical imaging and MRI10.3389/fmed.2021.712367 ↗
41. Macrophage-reprogramming upconverting nanoparticles for enhanced TAM-mediated antitumor therapy of hypoxic breast cancer10.1016/j.jconrel.2023.07.009 ↗
42. Targeted delivery of chlorogenic acid by mannosylated liposomes to effectively promote the polarization of TAMs for the treatment of glioblastoma
43. Regulation of M1-type and M2-type macrophage polarization in RAW264.7 cells by Galectin-910.3892/mmr.2017.7719 ↗
44. M2-like macrophages are responsible for collagen degradation through a mannose receptor-mediated pathway10.1083/jcb.201301081 ↗
45. Mannose-decorated hybrid nanoparticles for enhanced macrophage targeting
46. Mannose receptor (CD206) activation in tumor-associated macrophages enhances adaptive and innate antitumor immune responses10.1126/scitranslmed.aax6337 ↗
47. Hypoxia-induced scleral HIF-2α upregulation contributes to rises in MMP-2 expression and myopia development in mice10.1167/iovs.63.8.2 ↗
48. p21(WAF1/Cip1) regulation by hYSK1 activates SP-1 transcription factor and increases MMP-2 expression under hypoxic conditions10.3390/ijms20020310 ↗
49. Targeted imaging of CD206 expressing tumor-associated M2-like macrophages using mannose-conjugated antibiofouling magnetic iron oxide nanoparticles10.1021/acsabm.0c00368 ↗
50. Mannose attenuates colitis-associated colorectal tumorigenesis by targeting tumor-associated macrophages10.15430/JCP.2022.27.1.31 ↗
51. MMP-responsive nanomaterials10.1039/D3BM00840A ↗
52. Reprogramming hypoxic tumor‐associated macrophages by nanoglycoclusters for boosted cancer immunotherapy10.1002/adma.202211332 ↗
53. Macrophages in immunoregulation and therapeutics
54. Mannose receptor modulates macrophage polarization and allergic inflammation through miR-511-3p10.1016/j.jaci.2017.04.049 ↗
55. Targeting of tumor-associated macrophages made possible by PEG-sheddable, mannose-modified nanoparticles10.1021/mp400216r ↗
56. Mannose-modified hyaluronic acid nanocapsules for the targeting of tumor-associated macrophage10.1007/s13346-022-01265-9 ↗
57. Tumor vascular permeability and the EPR effect in macromolecular therapeutics: a review10.1016/S0168-3659(99)00248-5 ↗
58. Advanced NIR-II fluorescence imaging technology for precise evaluation of nanomedicine delivery in cancer therapy10.3390/chemosensors12060113 ↗
59. Targeted macrophage mannose receptor (CD206)-specific protein delivery via engineered extracellular vesicles10.1016/j.heliyon.2024.e40940 ↗
60. New perspectives in cell adhesion: RGD and integrins10.1126/science.2821619 ↗
61. Integrin alpha9beta1: unique signaling pathways reveal diverse biological roles10.4161/cam.4.2.10900 ↗
62. Cross-talk between HIF and PD-1/PD-L1 pathways in carcinogenesis and therapy10.1172/JCI159473 ↗
63. The relationship between expression of PD-L1 and HIF-1α in glioma cells under hypoxia10.1186/s13045-021-01102-5 ↗
64. Hypoxia-inducible factor-2α directly promotes BCRP expression and mediates the resistance of ovarian cancer stem cells to adriamycin10.1002/1878-0261.12419 ↗